ABOUT KALOCYTE
KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, is located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was incorporated in 2016 by co-founders Dr. Doctor, Dipanjan Pan, PhD and Phil Spinella, MD – expert researchers in physiology, bioengineering, and trauma care. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $14M in NIH and DOD grants and over $5M in investor funding.
KaloCyte History
- Raised $1M Convertible Note
- Expanded space, scientific team and expertise (total 8 employees)
- Entered national phase in 11 target countries/regions for EM V2 (lead product)
- Filed joint IP with UMB for EM clearance system
- Raised $1M Convertible Note
- Expanded scientific team with 2 new scientists (total 5 FTEs)
- Awarded NIH CRP SB1 grant ($500K/1Y)
- EM V2 patent filed and published (US and PCT)
- Held Pre-IND Meeting with FDA CBER
- Raised $1M Convertible Note
- Filed provisional patent application for lead candidate, EM V2
- Moved to Baltimore, MD
- Leased lab and office space in CBOTH at UMB as a UM BioPark Affiliate
- Awarded NIH Ph1 SBIR grant ($375K/2Y)
- Participated in NIH CAP accelerator program
- Held INTERACT Meeting with FDA
- Am Society Hematology “Best of ASH” & press release
- NHLBI Fast Track STTR ($2M/3Y)
- DoD CDMRP ($3M/3Y)
- KaloCyte, Inc. formed as a Delaware C-Corporation
- Patents Issued, ‘Quick Start License’
- BOD and SAB forms
by Pan, Doctor & Spinella
at WashU in St. Louis
- Bench Pilot Work
Formulation demonstrates key requirements
Novel transfusion models - First in vivo POC
Efficacy for hemorrhagic shock and 70% blood exchange
Formulation V1 - First Funding & Support
CDI OAIF Grant ($1M/3Y)
Invention Disclosure (WUSTL)
Bear Cub award ($75K)
BioSTL Fundamentals
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by nearly $20M in federal grants and investor funding.